Retain in vivo–like function, without feeder cells
Adoptive cell transfer (ACT) is a rapidly emerging immunotherapy approach in which a patient’s own genetically engineered immune cells are used to attack and treat their cancers. The most promising type of ACT comes from chimeric antigen receptors (CARs), where a patient’s T cells are harvested and scientists add a receptor that binds to a protein on the cancerous cells. This technique is possible thanks to extensive research performed on activation and expansion of T cells. Here are four easy steps to activate T cells without using feeder cells, but with results similar to in vivo–activated cells.
Pro tip Counting cells is an important step to maintain reproducibility.
Pro tip Your cells are not exposed to the stress of being passed through a column when you use a negative isolation method.
Pro tip No need for antigen-presenting cells (APCs), mitogens, antigens or feeder cells. This technology outperforms traditional home-brew methods for generic activation (mitogens, ConA, soluble antibodies, etc.) and is well documented in the published literature.
Pro tip Sit back and relax as your T cells get activated.
Several T cell–related therapies are already in the clinic, including checkpoint inhibitors and CAR T cells. Since it allows scientists to precisely edit the genome, CRISPR is a valuable tool for T cell research. With CRISPR technology, T cells can be altered to improve their ability to destroy cancer cells. For best results, start with pure populations of T cells. Invitrogen Dynabeads bead-based kits highly enrich T cell populations without adding contaminants.
For Research Use Only. Not for use in diagnostic procedures.